| Published Application/Species/Sample/Dilution | Reference |
|---|
| Acharya P, Williams W, Henderson R, Janowska K, Manne K, Parks R, et al. A glycan cluster on the SARS-CoV-2 spike ectodomain is recognized by Fab-dimerized glycan-reactive antibodies. bioRxiv. 2020;: pubmed publisher |
| Yee J, Van Rompay K, Carpenter A, Nham P, Halley B, Iyer S, et al. SARS-CoV-2 surveillance for a non-human primate breeding research facility. J Med Primatol. 2020;: pubmed publisher |
| Lei H, Ye F, Liu X, Huang Z, Ling S, Jiang Z, et al. SARS-CoV-2 environmental contamination associated with persistently infected COVID-19 patients. Influenza Other Respir Viruses. 2020;: pubmed publisher |
| Wickenhagen A, Flagg M, Port J, Yinda C, Goldin K, Gallogly S, et al. Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology. Nat Commun. 2025;16:594 pubmed publisher |
| Zhang Z, Zhang Y, Cheng L, Zhang L, Yan Q, Liu X, et al. Defining the features and structure of neutralizing antibody targeting the silent face of the SARS-CoV-2 spike N-terminal domain. MedComm (2020). 2024;5:e70008 pubmed publisher |
| Deng W, Hu X, Tian X, Zhang Y, Shang W, Zhang L, et al. Peptidomimetic Analogues Act as Effective Inhibitors against SARS-CoV-2 by Blocking the Function of Cathepsin L. J Med Chem. 2024;67:17124-17143 pubmed publisher |
| Hud xe1 k A, Pusztai D, Letoha A, Letoha T. Mutual Inhibition of Antithrombin III and SARS-CoV-2 Cellular Attachment to Syndecans: Implications for COVID-19 Treatment and Vaccination. Int J Mol Sci. 2024;25: pubmed publisher |
| Geanes E, McLennan R, Pierce S, Menden H, Paul O, Sampath V, et al. SARS-CoV-2 envelope protein regulates innate immune tolerance. iScience. 2024;27:109975 pubmed publisher |
| Khalil B, Sharif Askari N, Hafezi S, Sharif Askari F, Al Anouti F, Hamid Q, et al. Vitamin D regulates COVID-19 associated severity by suppressing the NLRP3 inflammasome pathway. PLoS ONE. 2024;19:e0302818 pubmed publisher |
| Liu R, Natekar J, Kim K, Pathak H, Bhatnagar N, Raha J, et al. Multivalent and Sequential Heterologous Spike Protein Vaccinations Effectively Induce Protective Humoral Immunity against SARS-CoV-2 Variants. Vaccines (Basel). 2024;12: pubmed publisher |
| Prakash S, Dhanushkodi N, Singer M, Quadiri A, Zayou L, Vahed H, et al. A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster Mo. bioRxiv. 2024;: pubmed publisher |
| Bae M, Choi S, Kim J, Seo G, Lee Y. Temperature-insensitive label-free SARS-CoV-2 spike protein detection based on complementary refractive index and temperature dependence of multi-mode interference and grating resonance. Talanta. 2024;266:125091 pubmed publisher |
| Zak A, Hoang T, Yee C, Rizvi S, Prabhu P, Wen F. Pseudotyping Improves the Yield of Functional SARS-CoV-2 Virus-like Particles (VLPs) as Tools for Vaccine and Therapeutic Development. Int J Mol Sci. 2023;24: pubmed publisher |
| Chiuppesi F, Ortega Francisco S, Gutiérrez M, Li J, Ly M, Faircloth K, et al. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy. Vaccines (Basel). 2023;11: pubmed publisher |
| Liang T, Xiao S, Wu Z, Lv X, Liu S, Hu M, et al. Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein. Viruses. 2023;15: pubmed publisher |
| Morita R, Kubota Koketsu R, Lu X, Sasaki T, Nakayama E, Liu Y, et al. COVID-19 relapse associated with SARS-CoV-2 evasion from CD4+ T-cell recognition in an agammaglobulinemia patient. iScience. 2023;26:106685 pubmed publisher |
| Wussow F, Kha M, Kim T, Ly M, Yll Pico M, Kar S, et al. Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants. NPJ Vaccines. 2023;8:41 pubmed publisher |
| Jia T, Wu Y, Liao G, Lei Y, Wu Z, Yang F, et al. Stable and durable antibody responses in SARS-recovered donors vaccinated with inactivated SARS-CoV-2 vaccine. J Med Virol. 2023;95:e28662 pubmed publisher |
| Palestra F, Poto R, Ciardi R, Opromolla G, Secondo A, Tedeschi V, et al. SARS-CoV-2 Spike Protein Activates Human Lung Macrophages. Int J Mol Sci. 2023;24: pubmed publisher |
| Sun S, Li E, Zhao G, Tang J, Zuo Q, Cai L, et al. Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge. Biomaterials. 2023;292:121907 pubmed publisher |
| Kiyan Y, Schultalbers A, Chernobrivaia E, Tkachuk S, Rong S, Shushakova N, et al. Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate. Sci Rep. 2022;12:16878 pubmed publisher |
| Oh C, Nakamura T, Beutler N, Zhang X, Pi xf1 a Crespo J, Talantova M, et al. Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection. Nat Chem Biol. 2022;: pubmed publisher |
| Ebenig A, Muraleedharan S, Kazmierski J, Todt D, Auste A, Anzaghe M, et al. Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. Cell Rep. 2022;40:111214 pubmed publisher |
| Han J, Lee S, Kim J, Seo G, Lee Y. SARS-CoV-2 spike protein detection using slightly tapered no-core fiber-based optical transducer. Mikrochim Acta. 2022;189:321 pubmed publisher |
| Peng L, Fang Z, Renauer P, McNamara A, Park J, Lin Q, et al. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Rep. 2022;40:111160 pubmed publisher |
| Chiuppesi F, Zaia J, Faircloth K, Johnson D, Ly M, Karpinski V, et al. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. iScience. 2022;25:104745 pubmed publisher |
| Sun X, Yi C, Zhu Y, Ding L, Xia S, Chen X, et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nat Microbiol. 2022;7:1063-1074 pubmed publisher |
| Gregoire C, Spinelli L, Villazala Merino S, Gil L, Holgado M, Moussa M, et al. Viral infection engenders bona fide and bystander subsets of lung-resident memory B cells through a permissive mechanism. Immunity. 2022;55:1216-1233.e9 pubmed publisher |
| Song Y, Zhang H, Zhu Y, Zhao X, Lei Y, Zhou W, et al. Lysozyme Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Inflammation in Human Corneal Epithelial Cells. Invest Ophthalmol Vis Sci. 2022;63:16 pubmed publisher |
| Wussow F, Kha M, Faircloth K, Nguyen V, Iniguez A, Martinez J, et al. COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. iScience. 2022;25:104457 pubmed publisher |
| Ma Y, Wang Y, Dong C, Gonzalez G, Zhu W, Kim J, et al. SARS-CoV-2 Spike Stem Protein Nanoparticles Elicited Broad ADCC and Robust Neutralization against Variants in Mice. Small. 2022;18:e2200836 pubmed publisher |
| Nakayama E, Kubota Koketsu R, Sasaki T, Suzuki K, Uno K, Shimizu J, et al. Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2 N protein. Sci Rep. 2022;12:8108 pubmed publisher |
| Walters J, Schouest B, Patel A, Reuschel E, Schultheis K, Parzych E, et al. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates. Vaccine. 2022;40:2960-2969 pubmed publisher |
| Wen K, Bai C, Zhao H, Zhou P, Gao S, Guan H, et al. Low dose radiation therapy attenuates ACE2 depression and inflammatory cytokines induction by COVID-19 viral spike protein in human bronchial epithelial cells. Int J Radiat Biol. 2022;98:1532-1541 pubmed publisher |
| Li C, Lee A, Grigoryan L, Arunachalam P, Scott M, Trisal M, et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat Immunol. 2022;23:543-555 pubmed publisher |
| Wu P, Yang Q, Zhao X, Liu Q, Xi J, Zhang F, et al. A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals. Res Vet Sci. 2022;145:46-49 pubmed publisher |
| Li M, Liu J, Lu R, Zhang Y, Du M, Xing M, et al. Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19-convalescent individuals. J Allergy Clin Immunol. 2022;149:1225-1241 pubmed publisher |
| Chiuppesi F, Nguyen V, Park Y, Contreras H, Karpinski V, Faircloth K, et al. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. NPJ Vaccines. 2022;7:7 pubmed publisher |
| Hudák A, Veres G, Letoha A, Szilak L, Letoha T. Syndecan-4 Is a Key Facilitator of the SARS-CoV-2 Delta Variant's Superior Transmission. Int J Mol Sci. 2022;23: pubmed publisher |
| Mironov V, Shchugoreva I, Artyushenko P, Morozov D, Borbone N, Oliviero G, et al. Structure- and Interaction-Based Design of Anti-SARS-CoV-2 Aptamers. Chemistry. 2022;28:e202104481 pubmed publisher |
| Cecon E, Dam J, Jockers R. Detection of SARS-CoV-2 spike protein binding to ACE2 in living cells by TR-FRET. STAR Protoc. 2022;3:101024 pubmed publisher |
| Frasca D, Reidy L, Romero M, Diaz A, Cray C, Kahl K, et al. The majority of SARS-CoV-2-specific antibodies in COVID-19 patients with obesity are autoimmune and not neutralizing. Int J Obes (Lond). 2022;46:427-432 pubmed publisher |
| Wang W, Li S, Xu X, Yang C, Niu X, Yin S, et al. Danshensu alleviates pseudo-typed SARS-CoV-2 induced mouse acute lung inflammation. Acta Pharmacol Sin. 2022;43:771-780 pubmed publisher |
| Lassauniere R, Polacek C, Gram G, Frische A, Tingstedt J, Krüger M, et al. Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2. NPJ Vaccines. 2021;6:156 pubmed publisher |
| Amanat F, Strohmeier S, Meade P, Dambrauskas N, Muhlemann B, Smith D, et al. Vaccination with SARS-CoV-2 variants of concern protects mice from challenge with wild-type virus. PLoS Biol. 2021;19:e3001384 pubmed publisher |
| Pan T, Chen R, He X, Yuan Y, Deng X, Li R, et al. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduct Target Ther. 2021;6:420 pubmed publisher |
| Griffin B, Warner B, Chan M, Valcourt E, Tailor N, Banadyga L, et al. Host parameters and mode of infection influence outcome in SARS-CoV-2-infected hamsters. iScience. 2021;24:103530 pubmed publisher |
| Zhong C, Xia H, Adam A, Wang B, Hajnik R, Liang Y, et al. Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies. NPJ Vaccines. 2021;6:139 pubmed publisher |
| Li J, Xu D, Wang L, Zhang M, Zhang G, Li E, et al. Glycyrrhizic Acid Inhibits SARS-CoV-2 Infection by Blocking Spike Protein-Mediated Cell Attachment. Molecules. 2021;26: pubmed publisher |
| Jiang Z, Zhao T, Li C, Li Y, Huang C. 2D MOF-Based Photoelectrochemical Aptasensor for SARS-CoV-2 Spike Glycoprotein Detection. ACS Appl Mater Interfaces. 2021;13:49754-49761 pubmed publisher |
| Warner B, Santry L, Leacy A, Chan M, Pham P, Vendramelli R, et al. Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease. iScience. 2021;24:103219 pubmed publisher |
| An X, Martinez Paniagua M, Rezvan A, Sefat S, Fathi M, Singh S, et al. Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. iScience. 2021;24:103037 pubmed publisher |
| Nagai M, Moriyama M, Ichinohe T. Oral Bacteria Combined with an Intranasal Vaccine Protect from Influenza A Virus and SARS-CoV-2 Infection. MBio. 2021;12:e0159821 pubmed publisher |
| Stampfer S, Goldwater M, Jew S, Bujarski S, Regidor B, Daniely D, et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia. 2021;35:3534-3541 pubmed publisher |
| Cecon E, Burridge M, Cao L, Carter L, Ravichandran R, Dam J, et al. SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. Cell Chem Biol. 2021;: pubmed publisher |
| Garrido C, Hurst J, Lorang C, Aquino J, Rodriguez J, Pfeiffer T, et al. Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents. JCI Insight. 2021;6: pubmed publisher |
| Ku Z, Xie X, Hinton P, Liu X, Ye X, Muruato A, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595:718-723 pubmed publisher |
| Williams W, Meyerhoff R, Edwards R, Li H, Manne K, Nicely N, et al. Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell. 2021;184:2955-2972.e25 pubmed publisher |
| Garrett M, Galloway J, Chu H, Itell H, Stoddard C, Wolf C, et al. High-resolution profiling of pathways of escape for SARS-CoV-2 spike-binding antibodies. Cell. 2021;184:2927-2938.e11 pubmed publisher |
| Low J, Vaqueirinho D, Mele F, Foglierini M, Jerak J, Perotti M, et al. Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. Science. 2021;372:1336-1341 pubmed publisher |
| Luo S, Zhang P, Liu B, Yang C, Liang C, Wang Q, et al. Prime-boost vaccination of mice and rhesus macaques with two novel adenovirus vectored COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10:1002-1015 pubmed publisher |
| Guo Y, Huang L, Zhang G, Yao Y, Zhou H, Shen S, et al. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Nat Commun. 2021;12:2623 pubmed publisher |
| Harbour J, Lyski Z, Schell J, Thomas A, Messer W, Slifka M, et al. Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein. J Immunol. 2021;206:2596-2604 pubmed publisher |
| Kalnin K, Plitnik T, Kishko M, Zhang J, Zhang D, Beauvais A, et al. Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. NPJ Vaccines. 2021;6:61 pubmed publisher |
| Verma S, Joshi C, Silverstein R, He M, Carter E, Mysorekar I. SARS-CoV-2 colonization of maternal and fetal cells of the human placenta promotes alteration of local renin-angiotensin system. Med (N Y). 2021;2:575-590.e5 pubmed publisher |
| Akhter J, Quéromès G, Pillai K, Kepenekian V, Badar S, Mekkawy A, et al. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. Viruses. 2021;13: pubmed publisher |
| Bollavaram K, Leeman T, Lee M, Kulkarni A, Upshaw S, Yang J, et al. Multiple sites on SARS-CoV-2 spike protein are susceptible to proteolysis by cathepsins B, K, L, S, and V. Protein Sci. 2021;30:1131-1143 pubmed publisher |
| Zhao M, Yang W, Yang F, Zhang L, Huang W, Hou W, et al. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Target Ther. 2021;6:134 pubmed publisher |
| Ren W, Zhu Y, Wang Y, Shi H, Yu Y, Hu G, et al. Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry. PLoS Pathog. 2021;17:e1009392 pubmed publisher |
| Frasca D, Reidy L, Cray C, Diaz A, Romero M, Kahl K, et al. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PLoS ONE. 2021;16:e0245424 pubmed publisher |
| Bläckberg A, Fernström N, Sarbrant E, Rasmussen M, Sunnerhagen T. Antibody kinetics and clinical course of COVID-19 a prospective observational study. PLoS ONE. 2021;16:e0248918 pubmed publisher |
| Cotugno N, Ruggiero A, Bonfante F, Petrara M, Zicari S, Pascucci G, et al. Virological and immunological features of SARS-CoV-2-infected children who develop neutralizing antibodies. Cell Rep. 2021;34:108852 pubmed publisher |
| Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12:1577 pubmed publisher |
| He X, Chandrashekar A, Zahn R, Wegmann F, Yu J, Mercado N, et al. Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques. bioRxiv. 2021;: pubmed publisher |
| Lu S, Xie X, Zhao L, Wang B, Zhu J, Yang T, et al. The immunodominant and neutralization linear epitopes for SARS-CoV-2. Cell Rep. 2021;34:108666 pubmed publisher |
| Nunes Santos C, Kuehn H, Rosenzweig S. N-Glycan Modification in Covid-19 Pathophysiology: In vitro Structural Changes with Limited Functional Effects. J Clin Immunol. 2021;41:335-344 pubmed publisher |
| Wang D, Baudys J, Bundy J, Solano M, Keppel T, Barr J. Comprehensive Analysis of the Glycan Complement of SARS-CoV-2 Spike Proteins Using Signature Ions-Triggered Electron-Transfer/Higher-Energy Collisional Dissociation (EThcD) Mass Spectrometry. Anal Chem. 2020;92:14730-14739 pubmed publisher |
| Chang A, Croix M, Kenney P, Baron S, Hicar M. Serum Responses of Children With Kawasaki Disease Against Severe Acute Respiratory Syndrome Coronavirus 2 Proteins. Pediatr Infect Dis J. 2020;39:e366-e367 pubmed publisher |
| Du S, Cao Y, Zhu Q, Yu P, Qi F, Wang G, et al. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell. 2020;183:1013-1023.e13 pubmed publisher |
| Clausen T, Sandoval D, Spliid C, Pihl J, Perrett H, Painter C, et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020;: pubmed publisher |
| Chi X, Liu X, Wang C, Zhang X, Li X, Hou J, et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020;11:4528 pubmed publisher |
| Gorshkov K, Susumu K, Chen J, Xu M, Pradhan M, Zhu W, et al. Quantum Dot-Conjugated SARS-CoV-2 Spike Pseudo-Virions Enable Tracking of Angiotensin Converting Enzyme 2 Binding and Endocytosis. ACS Nano. 2020;14:12234-12247 pubmed publisher |
| Clausen T, Sandoval D, Spliid C, Pihl J, Painter C, Thacker B, et al. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. bioRxiv. 2020;: pubmed publisher |
| Kim S, Jin W, Sood A, Montgomery D, Grant O, Fuster M, et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res. 2020;:104873 pubmed publisher |
| Chiuppesi F, Salazar M, Contreras H, Nguyen V, Martinez J, Park S, et al. Development of a Synthetic Poxvirus-Based SARS-CoV-2 Vaccine. bioRxiv. 2020;: pubmed publisher |
| Moriyama M, Nagai M, Maruzuru Y, Koshiba T, Kawaguchi Y, Ichinohe T. Influenza Virus-Induced Oxidized DNA Activates Inflammasomes. iScience. 2020;23:101270 pubmed publisher |
| Feng S, Luan X, Wang Y, Wang H, Zhang Z, Wang Y, et al. Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein. Infect Genet Evol. 2020;85:104419 pubmed publisher |
| Ravichandran S, Coyle E, Klenow L, Tang J, Grubbs G, Liu S, et al. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. Sci Transl Med. 2020;12: pubmed publisher |
| Smith T, Patel A, Ramos S, Elwood D, Zhu X, Yan J, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11:2601 pubmed publisher |
| Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells. Cell. 2020;182:73-84.e16 pubmed publisher |
| Li X, Das I, Lepletier A, Addala V, Bald T, Stannard K, et al. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest. 2018;128:2613-2625 pubmed publisher |
| Raczy x144 ski J. Doc. Dr Tadeusz Betkowski. Pol Przegl Chir. 1967;39:97-9 pubmed |
| Kuwabara S. [Present status and problems of commercially available microbial discs]. Rinsho Byori. 1966;14:643-6 pubmed |
